


Chromatogram of Purified Compound 8 (TAT-Cys-PTP σ Dimer Acetate Salt)

**FIG. 1**




FIG. 2




FIG. 3




FIG. 4




FIG. 5

Effects of Compound 8 treatment in the rat model of spinal cord injury




FIG. 6

Effects of Compound 8 treatment in the rat model of spinal cord injury




FIG. 7





FIG. 8A






FIG. 9

Pharmacokinetic Profiles of Compound 7 in Rat Plasma Following IV or SC Administration at 1.75 or 10.5 mg/kg, Respectively




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15

End of study rate of improvement: BBB $\geq$ 10, Bladder score $\leq$ 2




FIG. 16

End of study rate of improvement: BBB=11, Bladder score ≤ 2




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21

Distinct colloidal behavior of Compound 3 and Compound 7




FIG. 22